Mastodon

Benzylpenicillin novocaine (Powder) Instructions for Use

Marketing Authorization Holder

Sintez PJSC (Russia)

ATC Code

J01CE09 (Benzylpenicillin procaine)

Active Substance

Procaine benzylpenicillin

Dosage Form

Bottle Rx Icon Benzylpenicillin novocaine Powder for suspension for intramuscular administration 600,000 IU: vial 1 or 10 pcs.

Dosage Form, Packaging, and Composition

Powder for preparation of suspension for intramuscular administration white in color, prone to clumping.

1 vial
Procaine benzylpenicillin* 600000 IU

* benzylpenicillin procaine (benzylpenicillin novocaine salt).

Colorless glass vials (1) – cardboard packs.
Colorless glass vials (10) – cardboard packs.

Clinical-Pharmacological Group

Penicillin antibiotic, destroyed by penicillinase

Pharmacotherapeutic Group

Systemic antibacterial agents; beta-lactam antibacterial agents, penicillins; beta-lactamase sensitive penicillins

Pharmacological Action

Bactericidal antibiotic from the group of biosynthetic penicillins. It suppresses the synthesis of the cell wall of microorganisms.

Active against gram-positive bacteria Staphylococcus spp., Streptococcus spp. (including Streptococcus pneumoniae), Corynebacterium diphtheriae, Bacillus anthracis; gram-negative bacteria: Neisseria gonorrhoeae, Neisseria meningitidis; anaerobic spore-forming rods; as well as Actinomyces spp., Spirochaetaceae.

It is not active against most gram-negative bacteria, rickettsiae, viruses, protozoa. Strains of microorganisms that produce penicillinase are resistant to the action of procaine benzylpenicillin. It is destroyed in an acidic environment.

The procaine salt of benzylpenicillin is characterized by a longer duration of action compared to the potassium and sodium salts.

Pharmacokinetics

After intramuscular administration, Tmax is 20-30 min. T1/2 is 30-60 min, in renal failure – 4-10 h or more. Plasma protein binding is 60%. It penetrates into organs, tissues and biological fluids, except for cerebrospinal fluid, eye tissue and prostate. It penetrates the blood-brain barrier when the meninges are inflamed. It is excreted by the kidneys unchanged.

Indications

Infectious and inflammatory diseases caused by susceptible pathogens: lobar and focal pneumonia, pleural empyema, bronchitis; sepsis, septic endocarditis (acute and subacute), peritonitis; meningitis; osteomyelitis; infections of the genitourinary system (pyelonephritis, pyelitis, cystitis, urethritis, gonorrhea, blennorrhea, syphilis, cervicitis), biliary tract (cholangitis, cholecystitis); wound infection, infections of the skin and soft tissues: erysipelas, impetigo, secondarily infected dermatoses; diphtheria; scarlet fever; anthrax; actinomycosis; ENT diseases, eye diseases.

ICD codes

ICD-10 code Indication
A22 Anthrax
A36 Diphtheria
A38 Scarlet fever
A40 Streptococcal sepsis
A41 Other sepsis
A42 Actinomycosis
A46 Erysipelas
A51 Early syphilis
A54 Gonococcal infection
G00 Bacterial meningitis, not elsewhere classified
H04.3 Acute and unspecified inflammation of lacrimal passages
H04.4 Chronic inflammation of lacrimal passages
H19.2 Keratitis and keratoconjunctivitis in other infectious and parasitic diseases classified elsewhere
I33 Acute and subacute endocarditis
J01 Acute sinusitis
J02 Acute pharyngitis
J03 Acute tonsillitis
J04 Acute laryngitis and tracheitis
J15 Bacterial pneumonia, not elsewhere classified
J20 Acute bronchitis
J32 Chronic sinusitis
J35.0 Chronic tonsillitis
J37 Chronic laryngitis and laryngotracheitis
J42 Unspecified chronic bronchitis
J86 Pyothorax (pleural empyema)
K65.0 Acute peritonitis (including abscess)
K81.0 Acute cholecystitis
K81.1 Chronic cholecystitis
K83.0 Cholangitis
L01 Impetigo
L02 Cutaneous abscess, furuncle and carbuncle
L03 Cellulitis
L08.0 Pyoderma
L08.8 Other specified local infections of skin and subcutaneous tissue
L30.3 Infectious dermatitis (infectious eczema)
M86 Osteomyelitis
N10 Acute tubulointerstitial nephritis (acute pyelonephritis)
N11 Chronic tubulointerstitial nephritis (chronic pyelonephritis)
N30 Cystitis
N34 Urethritis and urethral syndrome
N72 Inflammatory disease of cervix uteri (including cervicitis, endocervicitis, exocervicitis)
T79.3 Posttraumatic wound infection, not elsewhere classified
ICD-11 code Indication
1A61.Z Early syphilis, unspecified
1A7Z Gonococcal infection, unspecified
1B50 Scarlet fever
1B70.0Z Erysipelas, unspecified
1B70.1 Streptococcal cellulitis of the skin
1B70.2 Staphylococcal cellulitis of the skin
1B70.Z Bacterial cellulitis or lymphangitis caused by unspecified bacterium
1B72.0 Bullous impetigo
1B72.1 Nonbullous impetigo
1B72.Z Impetigo, unspecified
1B75.0 Furuncle
1B75.1 Carbuncle
1B75.2 Furunculosis
1B75.3 Pyogenic skin abscess
1B7Y Other specified pyogenic bacterial infections of skin or subcutaneous tissue
1B97 Anthrax
1C10.Z Actinomycosis, unspecified
1C17.Z Diphtheria, unspecified
1C44 Non-pyogenic bacterial infections of skin
1D01.0Z Bacterial meningitis, unspecified
1G40 Sepsis without septic shock
9A11.Z Disorders of the lacrimal passages, unspecified
9A1Z Diseases of the lacrimal system, unspecified
9A71 Infectious keratitis
BB4Z Acute or subacute endocarditis, unspecified
CA01 Acute rhinosinusitis
CA02.Z Acute pharyngitis, unspecified
CA03.Z Acute tonsillitis, unspecified
CA05 Acute laryngitis or tracheitis
CA0A.Z Chronic rhinosinusitis, unspecified
CA0F.Y Other specified chronic diseases of the palatine tonsils and adenoids
CA0G Chronic laryngitis or laryngotracheitis
CA20.1Z Chronic bronchitis, unspecified
CA40.0Z Bacterial pneumonia, unspecified
CA42.Z Acute bronchitis, unspecified
CA44 Pyothorax
DC12.0Z Acute cholecystitis, unspecified
DC12.1 Chronic cholecystitis
DC13 Cholangitis
DC50.0 Primary peritonitis
DC50.2 Peritoneal abscess
DC50.Z Peritonitis, unspecified
EA50.3 Staphylococcal scarlet fever
EA88.0Z Infectious dermatitis, unspecified
EB21 Pyoderma gangrenosum
FB84.Z Osteomyelitis or osteitis, unspecified
GB50 Acute tubulo-interstitial nephritis
GB51 Acute pyelonephritis
GB55.Z Chronic tubulo-interstitial nephritis, unspecified
GB5Z Renal tubulo-interstitial diseases, unspecified
GC00.Z Cystitis, unspecified
GC02.Z Urethritis and urethral syndrome, unspecified
NF0A.3 Posttraumatic wound infection, not elsewhere classified
GA0Z Inflammatory diseases of female genital tract, unspecified
XA5WW1 Cervix uteri

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

It is administered intramuscularly.

Intravenous and endolumbar administration is prohibited.

The average therapeutic dose for adults: single – 300,000 IU, daily – 600,000 IU. The maximum daily dose for adults is 1,200,000 IU.

For children under 1 year of age – 50,000-100,000 IU/kg/day, over 1 year – 50,000 IU/kg/day.

The frequency of administration is 1-2 times/day.

The duration of treatment, depending on the form and severity of the disease, ranges from 7-10 days to 2 months or more (septic endocarditis, sepsis).

Adverse Reactions

Allergic reactions hyperthermia, urticaria, skin rash, rash on mucous membranes, arthralgia, eosinophilia, angioedema, interstitial nephritis, bronchospasm; rarely – anaphylactic shock

Local reactions: pain and induration at the injection site.

If it enters the vascular bed tinnitus, visual impairment, fear, dizziness, short-term loss of consciousness.

When administered in high doses neurotoxic phenomena are possible – nausea, vomiting, increased reflex excitability, symptoms of meningism, convulsions, coma.

Contraindications

Hypersensitivity to the group of penicillins, allergy to procaine.

Use in Pregnancy and Lactation

Use with caution during pregnancy and during lactation (breastfeeding).

Use in Hepatic Impairment

The drug is approved for use in impaired liver function

Special Precautions

With caution: bronchial asthma, hay fever and other allergic diseases, decreased blood clotting activity, pregnancy, lactation period, renal failure.

If no effect is noted 2-3 days (maximum 5 days) after starting the drug, it is necessary to switch to the use of other antibiotics or combination therapy.

Due to the possibility of developing fungal lesions, it is advisable during long-term treatment with benzylpenicillin to prescribe B vitamins and vitamin C, and if necessary, nystatin and levorin.

It must be taken into account that the use of procaine benzylpenicillin in reduced doses or too early termination of treatment often leads to the emergence of resistant strains of pathogens.

When treating venereal diseases, if syphilis is suspected, before starting therapy and then for 4 months, it is necessary to conduct microscopic and serological studies.

If any allergic reaction occurs, immediate discontinuation of treatment is required.

Drug Interactions

Bactericidal antibiotics (including cephalosporins, vancomycin, rifampicin, aminoglycosides) act synergistically with procaine benzylpenicillin. Bacteriostatic antibiotics (including macrolides, chloramphenicol, lincosamides, tetracyclines) have an antagonistic effect.

It increases the effectiveness of indirect anticoagulants (by suppressing the intestinal microflora, it reduces the prothrombin index); reduces the effectiveness of oral contraceptives, drugs in the process of metabolism of which para-aminobenzoic acid is formed, ethinyl estradiol – the risk of developing breakthrough bleeding.

Diuretics, allopurinol, tubular secretion blockers, phenylbutazone, NSAIDs, by reducing tubular secretion, increase the concentration of benzylpenicillin.

Allopurinol increases the risk of allergic reactions (skin rash).

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Rx Only

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

TABLE OF CONTENTS